Breaking News

CureVac and EU Discuss Advanced Purchase Agreement

Outline a contract for CureVac’s potential COVID-19 vaccine.

By: Contract Pharma

Contract Pharma Staff

CureVac, a clinical-stage biopharmaceutical company, and the European Commission have concluded exploratory talks outlining an Advanced Purchase Agreement (APA) for CureVac’s potential mRNA-based COVID-19 vaccine.   The envisaged contract with the European Commission is intended to provide all EU Member States with up to 225 million doses and an option for an additional purchase of 180 million doses, to be supplied once CureVac’s mRNA-based vaccine has proven to be safe and effective against COV...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters